International health bodies and patient groups have officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). the shift, announced after a survey of nearly 15,000 patients and clinicians, seeks to reflect the disorder’s hormonal and metabolic complexity and to improve treatment pathways for the estimated 170 million women affected.

56 Organizations Back the PMOS Rebranding

A consortium of 56 academic, clinical and advocacy groups voted to replace the PCOS label after concluding the old term misled both patients and providers. According to the World Health Organization, the conditon impacts roughly 10% to 13% of women of reproductive age, yet the name “polycystic ovary syndrome” suggested a narrow ovarian focus that often delayed proper diagnosis.

15,000 Surveyed Voices Reveal Stigma and Misdiagnosis

The joint survey of almost 15,000 individuals living with the syndrome and their healthcarre providers found that many felt the term PCOS reinforced stigma and limited care options. respondents reported that the cyst‑centric name diverted attention from metabolic symptoms such as insulin resistance,weight gain and cardiovascular risk, leading to fragmented treatment plans.

Dr. Helena Teede Highlights Funding Gaps Tied to Naming

Dr. Helena Teede, an endocrinologist at Monash University and lead author of the rebranding paper, warned that organ‑specific labels can shrink research budgets. she explained that “conditions viewed as primarily affecting a single organ often lead to limited funding, education, and treatment guidelines,” a point echoed by the consortium’s findings.

170 Million Women Stand to Gain Holistic Care

By foregrounding endocrine and metabolic dysfunction, the PMOS label is expected to attract broader research investment and multidisciplinary clinical teams.. Experts anticipate that cardiologists , endocrinologists and primary‑care physicians will join gynecologists in managing the syndrome’s full spectrum, from acne and hirsutism to heightened risks of type 2 diabetes, endometrial cancer and hypertension.

Will Insurers Adopt the PMOS Label?

One unresolved issue is whether health insurers will update coding and coverage policies to reflect the new terminology. The source notes that insurance reimbursement often lags behind clinical nomenclature, leaving a gap that could delay the promised benefits of the rebrand.

According to the consortium’s paper, the global renaming effort also aims to influence health policy, boost public awareness and streamline patient pathways across specialties. As the medical community begins to use PMOS, the hope is that diagnostic criteria will become more inclusive, reducing the current under‑diagnosis rates that plague women worldwide.